title: Safety of Drugs during Pregnancy and Breastfeeding in Cystic Fibrosis Patients.
abstract: Health management of cystic fibrosis (CF) patients should be maximized during pregnancy and breastfeeding because of its significant impact on the maternal and newborn outcomes. Thus, numerous drugs will have to be continued during pregnancy and lactation. Most of the drugs representing CF treatment lines cross the placenta or are excreted into human milk. Research addressing the risks and benefits of drugs used in CF patients during pregnancy and lactation is often incomplete or challenged by limited methodology, which often leads to conflicting or inconclusive results. Yet, potential treatment benefits for CF pregnant patients most often outbalance potential risks for the unborn child.
authors.affiliation: School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva, Switzerland.
authors.forename: Alice
authors.initials: A
authors.lastname: Panchaud
authors.forename: Ermindo R
authors.initials: ER
authors.lastname: Di Paolo
authors.forename: Angela
authors.initials: A
authors.lastname: Koutsokera
authors.forename: Ursula
authors.initials: U
authors.lastname: Winterfeld
authors.forename: Etienne
authors.initials: E
authors.lastname: Weisskopf
authors.forename: David
authors.initials: D
authors.lastname: Baud
authors.forename: Alain
authors.initials: A
authors.lastname: Sauty
authors.forename: Chantal
authors.initials: C
authors.lastname: Csajka
mesh_terms: D001942:Breast Feeding; D003550:Cystic Fibrosis / Q000188:drug therapy*; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005333:Fetus / Q000187:drug effects; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D013723:Teratogens
chemical_list: D013723:Teratogens